SCM
ACRS icon

Soleus Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Soleus Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-151,000
Closed -$1.57M – 92
2023
Q2 		$1.57M Sell
151,000
-98,000
-39% -$887K 0.17% 78
2023
Q1 		$2.01M Buy
+249,000
New +$3.16M 0.21% 64

Other funds holding ACRS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Soleus Capital Management's ACRS Position: Q3 2023 in Review

Soleus Capital Management sold out of Aclaris Therapeutics (ACRS) in Q3 2023, closing a stake of 151,000 shares — an estimated $1.57M sold.

Soleus Capital Management first reported a position in ACRS in Q1 2023 and held it in 2 quarters. The position peaked at $2.01M in Q1 2023. 137 funds tracked by Wall St. Rank hold ACRS as of Q3 2023.

  • Soleus Capital Management reported no remaining Aclaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Soleus Capital Management sold 151,000 Aclaris Therapeutics shares in Q3 2023, an estimated $1.57M.
  • Soleus Capital Management first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 2 quarters.
  • Soleus Capital Management's Aclaris Therapeutics position peaked at $2.01M in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.